Voya Investment Management LLC Boosts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Voya Investment Management LLC raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 149.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,033 shares of the company's stock after purchasing an additional 18,000 shares during the quarter. Voya Investment Management LLC owned 0.08% of Tarsus Pharmaceuticals worth $1,663,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $25,000. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $53,000. HighTower Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $207,000. Summit Investment Advisors Inc. boosted its position in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after acquiring an additional 244 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Tarsus Pharmaceuticals during the fourth quarter valued at $223,000. 90.01% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Trading Down 4.8 %

Shares of Tarsus Pharmaceuticals stock traded down $2.27 during trading on Friday, hitting $44.87. The stock had a trading volume of 529,648 shares, compared to its average volume of 689,849. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm's fifty day simple moving average is $48.26 and its 200-day simple moving average is $49.07. The stock has a market cap of $1.89 billion, a PE ratio of -11.78 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. As a group, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on TARS shares. The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research note on Monday, May 5th. Guggenheim raised their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group upped their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has an average rating of "Buy" and a consensus price target of $66.33.

Insider Transactions at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 2,137 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the transaction, the insider now owns 46,355 shares of the company's stock, valued at $2,322,849.05. This trade represents a 4.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 7,131 shares of Tarsus Pharmaceuticals stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the sale, the chief executive officer now owns 70,720 shares of the company's stock, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,542 shares of company stock worth $1,581,173. 8.25% of the stock is currently owned by company insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.